AZMIRO Drug Patent Profile
When do Azmiro patents expire, and when can generic versions of Azmiro launch?
Azmiro is a drug marketed by Azurity and is included in one NDA. There are three patents protecting this drug.
The generic ingredient in AZMIRO is testosterone cypionate. There is one drug master file entry for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the testosterone cypionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Azmiro
A generic version of AZMIRO was approved as testosterone cypionate by PADAGIS US on January 31st, 2005.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for AZMIRO?
- What are the global sales for AZMIRO?
- What is Average Wholesale Price for AZMIRO?
Summary for AZMIRO
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 3,859 |
| What excipients (inactive ingredients) are in AZMIRO? | AZMIRO excipients list |
| DailyMed Link: | AZMIRO at DailyMed |
Pharmacology for AZMIRO
| Drug Class | Androgen |
| Mechanism of Action | Androgen Receptor Agonists |
US Patents and Regulatory Information for AZMIRO
AZMIRO is protected by three US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | AZMIRO | testosterone cypionate | SOLUTION;INTRAMUSCULAR | 216318-001 | Jun 2, 2022 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Azurity | AZMIRO | testosterone cypionate | SOLUTION;INTRAMUSCULAR | 216318-001 | Jun 2, 2022 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Azurity | AZMIRO | testosterone cypionate | SOLUTION;INTRAMUSCULAR | 216318-001 | Jun 2, 2022 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
